THOC2

Across TCGA pan-cancer cohorts, THOC2 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated THOC2 data layer compared with 26 for mass-spec protein and 10 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher THOC2 mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated THOC2 expression acts as an unfavorable survival marker, although some lineages such as LUAD and LSCC show a favorable association.

PDAC, LUAD, and CCRCC are the cancer types where THOC2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	OS	Median	II,III,IV	0.370	0.716	<.001	30	view →
LUAD	OS	Median	II,III,IV	1.000	0.862	.004	26	view →
CCRCC	DFS	Quartile	II,III,IV	0.765	1.000	.005	18	view →
HNSC	DFS	Median	All	0.698	1.000	.020	9	view →
LSCC	DFS	Tertile	II,III,IV	0.887	0.437	.006	8	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

THOC2–PDAC (OS)

Open the PDAC breakdown →